The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Second-Line Oxaliplatin, Folinic Acid, and Fluorouracil Versus Folinic Acid and Fluorouracil Alone for Gemcitabine-Refractory Pancreatic Cancer: Outcomes From the CONKO-003 Trial
Abstract
Purpose: To assess the efficacy of a second-line regimen of oxaliplatin and folinic acid–modulated fluorouracil in patients with advanced pancreatic cancer who have experienced progression while receiving gemcitabine monotherapy. Patients and Methods: A randomized, open-label, phase III study was conducted in 16 institutions throughout Germany. Recruitment ran from January 2004 until May 2007, and the last follow-up concluded in December 2012. Overall, 168 patients age 18 years or older who experienced disease progression during first-line gemcitabine therapy were randomly assigned to folinic acid and fluorouracil (FF) or oxaliplatin and FF (OFF). Patients were stratified according to the presence of metastases, duration of first-line therapy, and Karnofsky performance status. Results: Median follow-up was 54.1 months, and 160 patients were eligible for the primary analysis. The median overall survival in the OFF group (5.9 months; 95% CI, 4.1 to 7.4) versus the FF group (3.3 months; 95% CI, 2.7 to 4.0) was significantly improved (hazard ratio [HR], 0.66; 95% CI, 0.48 to 0.91; log-rank P = .010). Time to progression with OFF (2.9 months; 95% CI, 2.4 to 3.2) versus FF (2.0 months; 95% CI, 1.6 to 2.3) was significantly extended also (HR, 0.68; 95% CI, 0.50 to 0.94; log-rank P = .019). Rates of adverse events were similar between treatment arms, with the exception of grades 1 to 2 neurotoxicity, which were reported in 29 patients (38.2%) and six patients (7.1%) in the OFF and FF groups, respectively (P < .001). Conclusion: Second-line OFF significantly extended the duration of overall survival when compared with FF alone in patients with advanced gemcitabine-refractory pancreatic cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
Conroy, T., Desseigne, F., Ychou, M., Bouché, O., Guimbaud, R., Bécouarn, Y., Adenis, A., Raoul, J.-L., Gourgou-Bourgade, S., de la Fouchardière, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1011923 · Cited by 7,810
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
Von Hoff, D. D., Ervin, T., Arena, F. P., Chiorean, E. G., Infante, J., Moore, M., Seay, T., Tjulandin, S. A., Ma, W. W., Saleh, M. N., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1304369 · Cited by 6,712
Burris, H. A., Moore, M. J., Andersen, J., Green, M. R., Rothenberg, M. L., Modiano, M. R., Cripps, M. C., Portenoy, R. K., Storniolo, A. M., Tarassoff, P., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.6.2403 · Cited by 5,894
Moore, M. J., Goldstein, D., Hamm, J., Figer, A., Hecht, J. R., Gallinger, S., Au, H. J., Murawa, P., Walde, D., Wolff, R. A., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.9525 · Cited by 3,848
Pelzer, U., Schwaner, I., Stieler, J., Adler, M., Seraphin, J., Dörken, B., Riess, H., & Oettle, H. (2011) · European Journal of Cancer · doi:10.1016/j.ejca.2011.04.011 · Cited by 370
Self-citationOral mTOR inhibitor everolimus in patients with gemcitabine-refractory metastatic pancreatic cancer
Wolpin, B. M., Hezel, A. F., Abrams, T., Blaszkowsky, L. S., Meyerhardt, J. A., Chan, J. A., Enzinger, P. C., Allen, B., Clark, J. W., Ryan, D. P., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.9514 · Cited by 297
Bodoky, G., Timcheva, C., Spigel, D. R., La Stella, P. J., Ciuleanu, T. E., Pover, G., & Tebbutt, N. C. (2012) · Investigational New Drugs · doi:10.1007/s10637-011-9687-4 · Cited by 236
Yoo, C., Hwang, J. Y., Kim, J.-E., Kim, T. W., Lee, J. S., Park, D. H., Lee, S. S., Seo, D. W., Lee, S. K., Kim, M.-H., et al. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605374 · Cited by 170
Capecitabine Plus Erlotinib in Gemcitabine-Refractory Advanced Pancreatic Cancer
Kulke, M. H., Blaszkowsky, L. S., Ryan, D. P., Clark, J. W., Meyerhardt, J. A., Zhu, A. X., Enzinger, P. C., Kwak, E. L., Muzikansky, A., Lawrence, C., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.8521 · Cited by 166
Xiong, H. Q., Varadhachary, G. R., Blais, J. C., Hess, K. R., Abbruzzese, J. L., & Wolff, R. A. (2008) · Cancer · doi:10.1002/cncr.23810 · Cited by 143
Rahma, O. E., Duffy, A. G., Liewehr, D. J., Steinberg, S. M., & Greten, T. F. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt166 · Cited by 140
Self-citationDemols, A., Peeters, M., Polus, M., Maréchal, R., Gay, F., Monsaert, E., Hendlisz, A., & Laethem, J. V. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6602966 · Cited by 138
Tsavaris, N. B., Kosmas, C., Skopelitis, H., Gouveris, P., Kopteridis, P., Loukeris, D., Sigala, F., Zorbala, A., Felekouras, E. S., & Papalambros, E. L. (2005) · Investigational New Drugs · doi:10.1007/s10637-005-1446-y · Cited by 103
Paclitaxel as weekly second-line therapy in patients with advanced pancreatic carcinoma
Oettle, H., Arnold, D., Esser, M., Huhn, D., & Riess, H. (2000) · Anti-Cancer Drugs · doi:10.1097/00001813-200009000-00006 · Cited by 92
Self-citationBoeck, S. H., Weigang-Köhler, K., Fuchs, M., Kettner, E., Quietzsch, D., Trojan, J., Stötzer, O. J., Zeuzem, S., Lordick, F., Köhne, C.-H., et al. (2007) · Annals of Oncology · doi:10.1093/annonc/mdl463 · Cited by 68
O'Reilly, E. M., Niedzwiecki, D., Hall, M., Hollis, D. R., Bekaii‐Saab, T., Pluard, T., Douglas, K., Abou‐Alfa, G. K., Kindler, H. L., Schilsky, R. L., et al. (2010) · The Oncologist · doi:10.1634/theoncologist.2010-0152 · Cited by 67
Irinotecan monotherapy as second-line treatment in advanced pancreatic cancer
Yi, S. Y., Park, Y. S., Kim, H. S., Jun, H. J., Kim, K. H., Chang, M. H., Park, M. J., Uhm, J. E., Lee, J., Park, S. H., et al. (2008) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-008-0839-y · Cited by 64
Androulakis, N., Syrigos, K., Polyzos, A., Aravantinos, G., Stathopoulos, G. P., Ziras, N., Mallas, K., Vamvakas, L. N., Georgoulias, V., & Research, F. T. H. O. (2005) · Cancer Investigation · doi:10.1081/cnv-46502 · Cited by 42
Astsaturov, I. A., Meropol, N. J., Alpaugh, R. K., Burtness, B. A., Cheng, J. D., McLaughlin, S., Rogatko, A., Xu, Z., Watson, J. C., Weiner, L. M., et al. (2010) · American Journal of Clinical Oncology · doi:10.1097/coc.0b013e3181d2734a · Cited by 41
Oxaliplatin, 5-Fluorouracil, and Leucovorin as Second-Line Treatment for Advanced Pancreatic Cancer
Novarino, A., Satolli, M. A., Chiappino, I., Giacobino, A., Bellone, G., Rahimi, F., Milanesi, E., Bertetto, O., & Ciuffreda, L. (2009) · American Journal of Clinical Oncology · doi:10.1097/coc.0b013e31817be5a9 · Cited by 36
Second-Line Therapy in Refractory Pancreatic Cancer. Results of a Phase II Study
Pelzer, U., Stieler, J., Roll, L., Hilbig, A., Dörken, B., Riess, H. B., & Oettle, H. (2009) · Oncology Research and Treatment · doi:10.1159/000197769 · Cited by 33
Self-citationS-1 Monotherapy as Second-line Treatment for Advanced Pancreatic Cancer after Gemcitabine Failure
Todaka, A., Fukutomi, A., Boku, N., Onozawa, Y., Hironaka, S., Yasui, H., Yamazaki, K., Taku, K., Machida, N., Sakamoto, T., et al. (2010) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyq005 · Cited by 28
Renouf, D. J., Tang, P. A., Major, P. P., Krzyzanowska, M. K., Dhesy-Thind, B., Goffin, J. R., Hedley, D. W., Wang, L. E., Doyle, L. M., & Moore, M. J. (2011) · Investigational New Drugs · doi:10.1007/s10637-011-9673-x · Cited by 26
Options for the Treatment of Gemcitabine-Resistant Advanced Pancreatic Cancer
Gounaris, I., Zaki, K. A., & Corrie, P. G. (2016) · PubMed · doi:10.6092/1590-8577/3842 · Cited by 20
Second-line therapy for gemcitabine-refractory pancreatic cancer: is there a standard?
Almhanna, K., & Kim, R. (2008) · PubMed · Cited by 16
Cited by
Whole genomes redefine the mutational landscape of pancreatic cancer
Initiative, A. P. C. G., Waddell, N., Pajic, M., Patch, A.-M., Chang, D. K., Kassahn, K. S., Bailey, P., Johns, A. L., Miller, D., Nones, K., et al. (2015) · Nature · doi:10.1038/nature14169 · Cited by 2,642
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A., Elias, A. D., Farrar, W. B., Forero, A., Giordano, S. H., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0012 · Cited by 1,609
Pancreatic Adenocarcinoma, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
Tempero, M. A., Malafa, M. P., Al-Hawary, M., Behrman, S. W., Benson, A. B., Cardin, D. B., Chiorean, E. G., Chung, V., Czito, B., Del Chiaro, M., et al. (2021) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2021.0017 · Cited by 1,304
Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Ducreux, M., Cuhna, A. S., Caramella, C., Hollebecque, A., Burtin, P., Goéré, D., Seufferlein, T., Haustermans, K., Van Laethem, J. L., Conroy, T., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv295 · Cited by 1,300
Wang-Gillam, A., Li, C.-P., Bodoky, G., Dean, A., Shan, Y.-S., Jameson, G., Macarulla, T., Lee, K.-H., Cunningham, D., Blanc, J. F., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00986-1 · Cited by 1,222
Self-citation
Metadata
- Authors
- Oettle, H., Riess, H., Stieler, J. M., Heil, G., Schwaner, I., Seraphin, J., Görner, M., Mölle, M., Greten, T. F., Lakner, V., Bischoff, S., Sinn, M., Dörken, B., & Pelzer, U.
- Venue
- Journal of Clinical Oncology
- Published
- 2014-08-10
- Volume
- 32
- Issue
- 23
- Pages
- 2423-2429
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2158798157
- Cited by
- 487
- References
- 25
- FWCI
- 21.69
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.